Pacira BioSciences, Inc.
PCRX
$24.08
$0.010.04%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 5.43M | -4.85M | 4.81M | 16.04M | -143.47M |
| Total Depreciation and Amortization | 15.69M | 27.32M | 21.17M | 21.24M | 20.25M |
| Total Amortization of Deferred Charges | 682.00K | 872.00K | 867.00K | 868.00K | 863.00K |
| Total Other Non-Cash Items | 55.02M | 26.87M | 7.39M | 19.31M | 174.18M |
| Change in Net Operating Assets | -16.00M | -38.20M | 1.22M | -24.33M | 2.09M |
| Cash from Operations | 60.83M | 12.01M | 35.46M | 33.13M | 53.92M |
| Capital Expenditure | -3.87M | -2.70M | -8.55M | -2.12M | -4.09M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 0.00 | 0.00 | -16.70M | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 47.48M | 64.86M | -379.00K | 1.75M | -48.07M |
| Cash from Investing | 43.61M | 62.16M | -25.63M | -368.00K | -52.16M |
| Total Debt Issued | 101.00M | -- | -- | 0.00 | 0.00 |
| Total Debt Repaid | -306.24M | -3.75M | -2.81M | -2.81M | -2.81M |
| Issuance of Common Stock | 12.00K | 1.57M | -- | 934.00K | 0.00 |
| Repurchase of Common Stock | -50.05M | -55.32M | -181.00K | -77.00K | -32.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -2.20M | -- | -- | 0.00 | 0.00 |
| Cash from Financing | -257.48M | -57.51M | -2.99M | -1.96M | -2.85M |
| Foreign Exchange rate Adjustments | 133.00K | 204.00K | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -152.90M | 16.87M | 6.84M | 30.81M | -1.09M |